Fig. 7: Targeting EGFR stability inhibits lung cancer initiation and progression.

a A549 tumor growth curves under different treatment. b Quantitative analysis of metastatic nodule numbers from mice as described in a. c NCI-H1975 tumor growth curves under different treatment. d Quantitative analysis of metastatic nodule numbers from mice as described in c. Data in a–d are presented as means ± SEM, n = 8. e The EGFR–TRIB3 or EGFR–PKCα interaction in xenograft tumors from indicated mice were detected with CO-IP assays. Data are representatives of three assays. f Generation of orthotopic xenograft lung cancer model for investigating in vivo antitumor activity of SAH-JGZ4. g Representatives of bioluminescence images of orthotopic lung implanted mice at indicated times. h Survival curves for mice orthotopically lung implanted with A549 cells under indicated treatment. Statistical difference was determined by two-sided log-rank test, n = 14. i Survival curves for mice orthotopically lung implanted with NCI-H1975 cells under indicated treatment. Statistical difference was determined by two-sided log-rank test, n = 12. j Strategy for the evaluation of SAH-JGZ4 on tumor initiation capacity in vivo. k Frequency of tumorigenic cell and probability estimates were calculated according to Poisson statistics with the use of Extreme Limiting Dilution Analysis (ELDA) online software (http://bioinf.wehi.edu.au/software/elda/). The P indicates a statistically significant difference in TIC frequency between SAH-con or SAH-JGZ4. l Images of the patient-derived lung cancer organoids in 3D culture following vehicle or SAH-JGZ4 (5 μM) treatment for 7 days. Data are means ± SEM of three independent assays. Statistical significance between two groups was determined with two-tailed Student’s t test. Statistical significance among groups was determined by one-way ANOVA test. Source data are provided as a Source Data file.